1016503-99-3 → HCID 58614628, compound

HRID 1364813Notes

Reaction equation

HRID 1364813 reaction equation
[Cl:1][C:2]1[CH:8]=[CH:7][C:5]([NH2:6])=[CH:4][C:3]=1[C:9]1[CH:14]=[CH:13][CH:12]=[CH:11][N:10]=1.[OH:15][CH:16]1[CH2:21][CH2:20][N:19]([S:22]([C:25]2[CH:33]=[CH:32][C:28]([C:29](O)=[O:30])=[CH:27][CH:26]=2)(=[O:24])=[O:23])[CH2:18][CH2:17]1>>[Cl:1][C:2]1[CH:8]=[CH:7][C:5]([NH:6][C:29](=[O:30])[C:28]2[CH:27]=[CH:26][C:25]([S:22]([N:19]3[CH2:18][CH2:17][CH:16]([OH:15])[CH2:21][CH2:20]3)(=[O:24])=[O:23])=[CH:33][CH:32]=2)=[CH:4][C:3]=1[C:9]1[CH:14]=[CH:13][CH:12]=[CH:11][N:10]=1

Participants

3

Reactant 2

HCID 180718081016503-99-3HCID 401519254-Chloro-3-(pyridin-2-yl)aniline

Product 1

HCID 58614628HCID 58614628, compound

Procedure

75 mg of 4-chloro-3-(pyridin-2-yl)aniline was coupled to 114 mg of 4-(4-hydroxypiperidin-1-ylsulfonyl)benzoic acid via Procedure G and purified by reverse phase HPLC to yield N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(4-hydroxypiperidin-1-ylsulfonyl)benzamide. MS (Q1) 472.3 (M)+.

Workup

  1. custompurified by reverse phase HPLC

Sources & evidence

ORD record
ord-9cf6b7a7fb604836b56c14e226340c12
Source dataset
uspto-grants-2011_02
Patent number
US07888364B2

Reaction notes

Loading…